Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 14/20 | 1.00 |
| ▸ | GRM3 | Q14832 | 14/20 | 1.00 |
| ▸ | GRM6 | O15303 | 11/20 | 1.00 |
| ▸ | GRM8 | O00222 | 7/20 | 1.00 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.73 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.73 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.46 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eglumetad SCHEMBL13319987 | 1.00 | GRM2 (1.00) | GRM2GRM3GRM6GRM8SLC1A2 | |
| Eglumetad SCHEMBL15060586 | 1.00 | GRM2 (1.00) | GRM2GRM3GRM6GRM8SLC1A2 | |
| Eglumetad SCHEMBL16585263 | 1.00 | GRM2 (1.00) | GRM2GRM3GRM6GRM8SLC1A2 | |
| Eglumetad SCHEMBL13728495 | 1.00 | GRM2 (1.00) | GRM2GRM3GRM6GRM8SLC1A2 | |
| Eglumetad SCHEMBL231157 | 1.00 | GRM2 (1.00) | GRM2GRM3GRM6GRM8SLC1A2 | |
| Eglumetad SCHEMBL1650783 | 0.98 | GRM2 (0.96) | GRM2GRM3GRM6GRM8SLC1A2 | |
| SCHEMBL30417494 | 0.85 | SLC1A2 (1.00) | GRM2GRM3GRM6GRM8SLC1A2 | |
| SCHEMBL6697973 | 0.80 | GRM2 (0.67) | GRM2GRM3GRM6GRM8SLC1A2 | |
| Hydrochloric Acid SCHEMBL4810986 | 0.79 | SLC1A2 (0.66) | GRM2GRM3GRM6GRM8SLC1A2 | |
| Hydrochloric Acid SCHEMBL6699648 | 0.79 | GRM2 (0.65) | GRM2GRM3GRM6GRM8SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023097186-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VISUAL FUNCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-01 | — | — | WO | claimed |
| EP-2704793-B1 | REGULATION OF AMYLOID BETA MOLECULAR COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE | UNIV RAMOT (IL) | 2019-07-17 | — | — | EP | claimed |
| US-20250295713-A1 | COMPOSITIONS AND METHODS FOR IMPROVING SKIN HEALTH AND FOR THE TREATMENT AND PREVENTION OF DISEASES, DISORDERS AND CONDITIONS ASSOCIATED WITH PATHOGENIC MICROBES | DERMBIONT, INC. | 2025-09-25 | — | — | US | disclosed |
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| US-20250152601-A1 | Compositions and Methods for the Treatment of Sexual Dysfunctions | THE JONATHAN HURT LIVING TRUST (US) | 2025-05-15 | — | — | US | disclosed |
| US-12064459-B2 | Compositions and methods for improving skin health and for the treatment and prevention of diseases, disorders and conditions associated with pathogenic microbes | DERMBIONT, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| US-11938106-B2 | Treatment of tinnitus using glutamate receptor agonists | NORTHEAST OHIO MEDICAL UNIVERSITY (US) | 2024-03-26 | — | — | US | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2024-03-07 | — | — | US | disclosed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11744812-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| EP-1110943-B1 | 6-FLUOROBICYCLO 3. 1.0]HEXANE DERIVATIVES | TAISHO PHARMACEUTICAL CO LTD (JP) | 2004-06-16 | — | — | EP | disclosed |
| US-20040077879-A1 | Bis (amino acid) molecular scaffolds | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2004-04-22 | — | — | US | disclosed |
| US-20040006114-A1 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2004-01-08 | — | — | US | disclosed |
| WO-2003045898-A1 | PRODRUGS OF EXCITATORY AMINO ACIDS | ELI LILLY AND COMPANY (US) | 2003-06-05 | — | — | WO | disclosed |
| EP-1052246-B1 | FLUORINE-CONTAINING AMINO ACID DERIVATIVES | TAISHO PHARMACEUTICAL CO LTD (JP) | 2003-04-02 | — | — | EP | disclosed |
| US-6333428-B1 | TREATMENT OR PREVENTION OF PSYCHIATRIC DISORDERS OR NEUROLOGICAL DISEASES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2001-12-25 | — | — | US | disclosed |
| US-6316498-B1 | FOR THERAPY AND PROPHYLAXIS OF PSYCHIATRIC DISORDERS SUCH AS SCHIZOPHRENIA, ANXIETY, ASSOCIATED DISEASES, DEPRESSION, BIPOLAR DISTURBANCE AND EPILEPSY, NEUROLOGICAL DISEASES SUCH AS DRUG ADDICTION, COGNITION DISORDER, ALZHEIMER'S DISEASE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2001-11-13 | — | — | US | disclosed |
| EP-1110943-A1 | 6-FLUOROBICYCLO 3. 1.0]HEXANE DERIVATIVES | Taisho Pharmaceutical Co. Ltd. (JP) | 2001-06-27 | — | — | EP | disclosed |
| EP-1052246-A1 | FLUORINE-CONTAINING AMINO ACID DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2000-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077879-A1 | Bis (amino acid) molecular scaffolds | DNPEP, BCAT1, BCAT2 | GRM2 1639/4885GRM3 663/4885GRM6 1882/4885 |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | GRM2 682/4885GRM3 977/4885GRM6 562/4885 |
| US-11744812-B2 | Methods of treatment | ACE2, ACE, SI | GRM2 130/4885GRM3 125/4885GRM6 583/4885 |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | GRM2 718/4885GRM3 1016/4885GRM6 570/4885 |
| US-20040006114-A1 | Potentiators of glutamate receptors | GRM1, GRIN1, GRM2 | GRM2 3/4885GRM3 6/4885GRM6 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.